OOIR: Observatory of International Research

Papers

(The H4-Index of Autoimmunity Reviews is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease	1234
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy	570
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions	494
Covid-19 and autoimmunity	394
Convalescent plasma in Covid-19: Possible mechanisms of action	364
The SARS-CoV-2 as an instrumental trigger of autoimmunity	333
COVID-19 infection and rheumatoid arthritis: Faraway, so close!	310
Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis	216
Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?	211
COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?	203
Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation	187
Rheumatoid arthritis: Extra-articular manifestations and comorbidities	165
Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning	163
Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review	149
The role of TH17 cells in multiple sclerosis: Therapeutic implications	140
SARS-CoV-2, the autoimmune virus	137
Post-COVID syndrome. A case series and comprehensive review	133
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases	130
Beyond the joints, the extra-articular manifestations in rheumatoid arthritis	128
SARS-CoV-2 infection among patients with systemic autoimmune diseases	123
Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis	121
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?	116
CCR6-CCL20 axis as a therapeutic target for autoimmune diseases	93
The influence of cytokines on the complex pathology of ulcerative colitis	91
A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors	91

Clinical outcome measures in multiple sclerosis: A review	89
Molecular mimicry may explain multi-organ damage in COVID-19	88
Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons	85
B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)	83
The IL-1 family cytokines and receptors in autoimmune diseases	82
An Overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand RANKL and related nutritional interventions	82
Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies	81
An updated advance of autoantibodies in autoimmune diseases	80
ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia	79
Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities	76
2020 international consensus on ANCA testing beyond systemic vasculitis	76
Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014	74
Rheumatoid arthritis in the elderly: Characteristics and treatment considerations	73
The autonomic aspects of the post-COVID19 syndrome	73
Novel insights into macrophage diversity in rheumatoid arthritis synovium	73
The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study	72
Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: Potential role in Sjögren’s syndrome	70
Rheumatological complications of Covid 19	69
Cytokine storm syndrome in severe COVID-19	67
Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis	66
Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies	58
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A systematic review	56
Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis	56
Exosomes: Effectual players in rheumatoid arthritis	54
The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis	53
Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia	53
Gender-related differences in systemic sclerosis	52